Table 5.
League table of hypoglycemia (upper right quarter) and GIAEs (lower left quarter).
| Placebo | 1.60 (0.03, 7.72) | 0.51 (0.01, 2.27) | 1.30 (0.70, 2.19) | 2.63 (0.46, 8.10) | 1.35 (0.30, 3.72) | 3,867,030.67 (0.00, 400,117.91) |
| NA |
Teneligliptin
5 mg |
2.13 (0.01, 16.00) | 9.39 (0.16, 39.22) | 21.77 (0.24, 75.01) | 9.84 (0.10, 42.35) | 5,377,343.72 (0.00, 947,506.86) |
| NA | NA |
Teneligliptin
10 mg |
15.44 (0.53, 87.30) | 26.63 (0.86, 149.16) | 16.56 (0.34, 89.05) | 7,695,257.57 (0.00, 1,838,505.19) |
| 0.76 (0.34, 1.28) | NA | NA |
Teneligliptin
20 mg |
2.13 (0.36, 6.88) | 1.03 (0.28, 2.69) | 2,438,052.60 (0.00, 340,812.34) |
| NA | NA | NA | NA |
Teneligliptin
40 mg |
0.85 (0.09, 3.32) | 2,299,670.23 (0.00, 224,503.51) |
| NA | NA | NA | NA | NA |
Sitagliptin
100 mg |
4,025,460.15 (0.00, 433,075.76) |
| 0.01 (0.00, 0.12) | NA | NA | 0.02 (0.00, 0.16) | NA | NA |
Bromocriptine
0.8 mg |
The relative effect sizes are measured as an odds ratio along with 95% CIs. The differences between the compared groups are deemed as significant when the 95% CIs did not contain 1.00. The results with significant differences are marked with blue background, and the results without significant differences are marked with gray background. The doses of all the antidiabetic drugs are daily dose. GIAEs, gastrointestinal adverse events; NA, not available.